Table 2 Incidence of the composite cardiovascular outcome by baseline risk.
| Without aspirin | HR (95% CI) | p Value | With aspirin | HR (95% CI) | p Value | |||
|---|---|---|---|---|---|---|---|---|
| Ibuprofen No (%) | Lumiracoxib No (%) | Ibuprofen No (%) | Lumiracoxib No (%) | |||||
| Ibuprofen substudy | ||||||||
| Overall | 13/3431 (0.38) | 13/3401 (0.38) | 1.06 (0.49 to 2.28) | 0.88 | 10/966 (1.04) | 6/975 (0.62) | 1.79 (0.65 to 4.93) | 0.26 |
| Low CV risk | 11/3181 (0.35) | 10/3075 (0.33) | 1.13 (0.48 to 2.66) | 0.77 | 2/593 (0.34) | 5/581 (0.86) | 0.40 (0.08 to 2.08) | 0.27 |
| High CV risk | 2/250 (0.80) | 3/326 (0.92) | 0.91 (0.15 to 5.47) | 0.92 | 8/373 (2.14) | 1/394 (0.25) | 9.08 (1.13 to 72.76) | 0.038 |
| Naproxen No (%) | Lumiracoxib No (%) | Naproxen No (%) | Lumiracoxib No (%) | |||||
| Naproxen substudy | ||||||||
| Overall | 14/3537 (0.40) | 22/3549 (0.62) | 0.67 (0.34 to 1.31) | 0.242 | 13/1193 (1.09) | 18/1192 (1.51) | 0.70 (0.35 to 1.44) | 0.337 |
| Low CV risk | 14/3202 (0.44) | 17/3231 (0.53) | 0.88 (0.43 to 1.78) | 0.714 | 5/688 (0.73) | 10/651 (1.54) | 0.45 (0.15 to 1.32) | 0.149 |
| High CV risk | 0/335 (0.00) | 5/318 (1.57) | Not applicable | 0.027* | 8/505 (1.58) | 8/541 (1.48) | 1.07 (0.40 to 2.84) | 0.899 |